DE602004031199D1 - Behandlung von igai-ablagerungserkrankungen - Google Patents

Behandlung von igai-ablagerungserkrankungen

Info

Publication number
DE602004031199D1
DE602004031199D1 DE602004031199T DE602004031199T DE602004031199D1 DE 602004031199 D1 DE602004031199 D1 DE 602004031199D1 DE 602004031199 T DE602004031199 T DE 602004031199T DE 602004031199 T DE602004031199 T DE 602004031199T DE 602004031199 D1 DE602004031199 D1 DE 602004031199D1
Authority
DE
Germany
Prior art keywords
iga1
treatment
deposition
igai
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031199T
Other languages
German (de)
English (en)
Inventor
Andrew G Plaut
Jiazhou Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Publication of DE602004031199D1 publication Critical patent/DE602004031199D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DE602004031199T 2003-03-07 2004-03-05 Behandlung von igai-ablagerungserkrankungen Expired - Lifetime DE602004031199D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45305503P 2003-03-07 2003-03-07
PCT/US2004/006615 WO2004096157A2 (en) 2003-03-07 2004-03-05 Treatment of igai deposition diseases

Publications (1)

Publication Number Publication Date
DE602004031199D1 true DE602004031199D1 (de) 2011-03-10

Family

ID=33418058

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031199T Expired - Lifetime DE602004031199D1 (de) 2003-03-07 2004-03-05 Behandlung von igai-ablagerungserkrankungen

Country Status (10)

Country Link
US (3) US7407653B2 (https=)
EP (1) EP1603511B1 (https=)
JP (4) JP5438886B2 (https=)
KR (2) KR20130026513A (https=)
CN (1) CN1777673B (https=)
AT (1) ATE496992T1 (https=)
CA (1) CA2558873C (https=)
DE (1) DE602004031199D1 (https=)
ES (1) ES2360291T3 (https=)
WO (1) WO2004096157A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603511B1 (en) * 2003-03-07 2011-01-26 New England Medical Center Hospitals, Inc. Treatment of igai deposition diseases
WO2007061936A2 (en) 2005-11-18 2007-05-31 New England Medical Center Hospitals, Inc. Clearance of abnormal iga1 in iga1 deposition diseases
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
TW201040266A (en) * 2009-04-10 2010-11-16 Biomarin Pharm Inc Methods of enhancing yield of active IgA protease
US8841109B2 (en) 2009-04-20 2014-09-23 The University Of Kansas IGA1 protease polypeptide agents and uses thereof
CN104073474A (zh) * 2014-06-27 2014-10-01 樊均明 一种IgA1酶及其制备方法和应用
WO2017223534A2 (en) * 2016-06-24 2017-12-28 Anthera Pharmaceuticals, Inc. Methods of treating iga nephropathy and henoch-schönlein purpura nephritis using a b-cell activating factor (baff) inhibitor
CN115197328B (zh) * 2021-04-09 2025-05-16 北京大学第一医院 一种可清除体内免疫球蛋白A的重组融合蛋白酶及其制备方法和在治疗IgA肾病中的应用
JP2025505131A (ja) * 2022-01-29 2025-02-21 ペキン ユニバーシティ ファースト ホスピタル ＩｇＡプロテアーゼトランケート、ＩｇＡプロテアーゼトランケートを含む融合タンパク質及びその用途
KR20250114034A (ko) 2022-11-11 2025-07-28 아이간 바이오사이언스 Iga 프로테아제 폴리펩타이드 제제
JP7736395B1 (ja) * 2024-02-29 2025-09-09 積水メディカル株式会社 免疫学的測定方法、免疫学的測定用試薬、免疫学的測定用検体前処理液、免疫学的測定用試薬キット、及び非特異反応抑制剤
WO2025237369A1 (en) * 2024-05-15 2025-11-20 Shanghai Alezyme Pharmaceuticals Ltd. Conjugates comprising iga protease or variants thereof and a polyethylene glycol moiety, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DK130889A (da) * 1989-03-17 1990-09-18 Mogens Kilian Immunoglobulin a1-proteaser (iga1-proteaser), fremgangsmaade til genteknologisk fremstilling af saadanne enzymer samt vaccine indeholdende enzymerne og fragmenter deraf til immunisering mod bakteriel meningitis og andre sygdomme fremkaldt af iga1-protease-producerende bakterier
US6429024B1 (en) * 1998-03-31 2002-08-06 Asahi Kasei Kabushiki Kaisha Test method for IgA nephropathy
DK2067788T3 (da) 1999-05-18 2015-10-19 Dyax Corp Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf
EP1603511B1 (en) 2003-03-07 2011-01-26 New England Medical Center Hospitals, Inc. Treatment of igai deposition diseases

Also Published As

Publication number Publication date
CN1777673A (zh) 2006-05-24
US20090041746A1 (en) 2009-02-12
HK1090950A1 (zh) 2007-01-05
ES2360291T3 (es) 2011-06-02
JP2011101645A (ja) 2011-05-26
US20090130084A1 (en) 2009-05-21
KR20130026513A (ko) 2013-03-13
JP2006519619A (ja) 2006-08-31
US8216568B2 (en) 2012-07-10
JP2015096079A (ja) 2015-05-21
EP1603511B1 (en) 2011-01-26
US7407653B2 (en) 2008-08-05
JP5438886B2 (ja) 2014-03-12
EP1603511A4 (en) 2007-06-06
JP2013230157A (ja) 2013-11-14
KR20060015468A (ko) 2006-02-17
CA2558873A1 (en) 2004-11-11
US20050136062A1 (en) 2005-06-23
WO2004096157A3 (en) 2005-10-20
ATE496992T1 (de) 2011-02-15
WO2004096157A2 (en) 2004-11-11
CA2558873C (en) 2015-10-20
CN1777673B (zh) 2010-04-28
EP1603511A2 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
DE602004031199D1 (de) Behandlung von igai-ablagerungserkrankungen
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
BR0317020A (pt) Derivados de hidroxietilamina para o tratamento de doença de alzheimer
NO20081084L (no) Arylpyridiner og fremgangsmater for deres anvendelse
TW200724157A (en) A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007022470A3 (en) Methods and compositions for treating neurological disease
MX2007012324A (es) Dispositivo y metodo para tratar condiciones del seno paranasal.
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
BR0214672A (pt) Inibidores de fosfolipase citosólica a2
GB0328900D0 (en) Novel compounds
DE60130872D1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2004024089A3 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2007074346A3 (en) Modulation of wnt signalling pathways for treating nervous system disorders
ATE464321T1 (de) Gentherapie des auges

Legal Events

Date Code Title Description
R081 Change of applicant/patentee

Ref document number: 1603511

Country of ref document: EP

Owner name: TUFTS MEDICAL CENTER, INC., US

Free format text: FORMER OWNER: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC., BOSTON, US

Effective date: 20121108

R082 Change of representative

Ref document number: 1603511

Country of ref document: EP

Representative=s name: WSL PATENTANWAELTE PARTNERSCHAFTSGESELLSCHAFT, DE

Effective date: 20121108